Diabetic foot ulcers represent one of the most devastating complications of diabetes mellitus. These wounds heal slowly, resist conventional treatment, and frequently lead to infection, hospitalization, and ultimately lower-extremity amputation. The statistics are sobering: mortality after a diabetic foot ulcer diagnosis reaches approximately 5% within the first year and climbs to 40% at five years. Against this backdrop, clinicians have long sought adjunctive therapies that might tip the balance toward healing. Hyperbaric oxygen therapy has emerged as one of the most extensively studied—and most debated—of these interventions.
Two major reviews published in 2026 have brought fresh analytical rigor to this longstanding clinical question. A narrative synthesis published in MDPI’s Medical Sciences applied GRADE methodology to evaluate the certainty of evidence across multiple diabetic foot ulcer therapies, while a comprehensive analysis from The Mayer Institute examined both the biological rationale and the practical limits of HBOT in contemporary wound care.
The Biological Case for Pressurized Oxygen
The mechanistic argument for HBOT in diabetic wounds rests on a straightforward physiological premise. Chronic diabetic foot ulcers typically exist in a state of tissue hypoxia. Peripheral arterial disease, microvascular dysfunction, and the heightened metabolic demands of infected tissue combine to starve the wound bed of oxygen just when repair processes require it most.
HBOT delivers 100% oxygen at pressures typically ranging from 2.0 to 2.5 atmospheres absolute, usually in 90-minute sessions administered five days weekly over four to six weeks. Under these conditions, the quantity of oxygen dissolved in plasma increases dramatically—sufficient to oxygenate tissues beyond the reach of compromised circulation. This superoxygenation is thought to stimulate angiogenesis, enhance neutrophil bactericidal activity, promote collagen synthesis and fibroblast proliferation, and reduce edema through vasoconstriction.
These mechanisms are biologically plausible and well-documented in experimental settings. Yet biological plausibility does not automatically translate into reliable clinical benefit, which is precisely why the 2026 evidence syntheses matter.
GRADE Assessment: Moderate Certainty with Important Caveats
The MDPI review represents a significant methodological advance over earlier syntheses. Rather than simply tallying statistically significant findings, the authors applied GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria to assess certainty of evidence across randomized controlled trials published between 2016 and 2026. This framework explicitly evaluates risk of bias, inconsistency between studies, indirectness of evidence, imprecision, and publication bias.
For hyperbaric oxygen therapy specifically, the review assigned moderate-certainty evidence based on pooled data from multiple RCTs reporting 12-week complete wound-healing rates. This places HBOT among the better-supported adjunctive therapies for diabetic foot ulcers, though the authors emphasized that certainty was limited by heterogeneity in interventions, comparators, and outcome definitions across studies.
The moderate GRADE rating represents a nuanced finding. It suggests that clinicians can have reasonable confidence in HBOT’s short-term healing benefits for appropriately selected patients, while acknowledging that the true effect size may differ from trial estimates. The rating also flags the need for better-standardized protocols and more consistent outcome reporting in future research.
What the Numbers Show—and Where They Fall Short
The 2015 Cochrane systematic review by Kranke and colleagues remains the most influential synthesis in this field. Pooling data from ten RCTs focused on diabetic foot ulcers, the review found that HBOT significantly increased healing rates at six weeks, with a risk ratio of 2.35. However, this early advantage did not persist at one-year follow-up, and the Cochrane authors rated the overall certainty of evidence as low due to methodological limitations in the underlying trials.
Subsequent meta-analyses have generally supported these findings while expanding the evidence base. A 2022 systematic review by Zhang and colleagues pooled 20 randomized trials encompassing over 1,200 patients, reporting that HBOT increased healing rates and shortened time to healing. A 2024 network meta-analysis by OuYang and colleagues positioned HBOT among several adjunctive therapies demonstrating superior complete healing compared with standard care alone.
The 2026 Mayer Institute analysis synthesized these findings with a critical eye toward clinical application. The review noted that while short-term healing benefits are reasonably well-established, several evidence gaps persist:
Long-term durability remains uncertain. The Cochrane finding that six-week benefits dissipated by one year has not been conclusively refuted by subsequent research. Whether HBOT produces lasting wound closure or merely accelerates healing that would have occurred anyway remains an open question.
Patient selection criteria lack precision. Not all diabetic foot ulcers respond equally to HBOT. Ischemic wounds, those with significant infection, and those failing multiple prior interventions may represent distinct subpopulations with different likelihoods of benefit. Current evidence does not clearly define which patients should receive priority for HBOT referral.
Optimal dosing is poorly standardized. Pressure levels, session duration, treatment frequency, and total number of sessions vary considerably across protocols. Whether more intensive regimens produce superior outcomes, or whether abbreviated courses might suffice for certain patients, remains largely unexplored.
The Outcome That Matters Most: Amputation Prevention
For patients and clinicians alike, the most consequential endpoint is not wound healing per se but preservation of the limb. Major lower-extremity amputation represents a catastrophic outcome with profound implications for mobility, independence, and survival.
Here the evidence offers somewhat stronger grounds for optimism. Multiple RCTs have reported significant reductions in major amputation risk among patients receiving adjunctive HBOT. The landmark randomized study by Faglia and colleagues demonstrated that HBOT substantially reduced major amputation rates in patients with severe diabetic foot ulcers, a finding that has been replicated in subsequent trials including the analysis by Kessler and colleagues showing accelerated healing trajectories.
The 2026 MDPI review specifically highlighted amputation prevention as an area where HBOT’s benefits appear most consistent across studies, though the authors again noted limitations in overall evidence certainty. Medicare coverage determinations have historically emphasized this amputation-prevention rationale in their reimbursement criteria.
FDA Clearance and Insurance Coverage
From a regulatory standpoint, diabetic foot ulcers occupy a distinctive position in HBOT’s indication landscape. The FDA has cleared hyperbaric oxygen therapy for “certain non-healing wounds,” specifically including Wagner Grade III or IV diabetic foot ulcers that have failed standard wound care. This clearance, while narrower than some proponents might prefer, provides a legitimate regulatory foundation for clinical use.
Medicare coverage under National Coverage Determination 20.29 extends to diabetic foot ulcers meeting specific criteria: the wound must be Wagner Grade III or higher, and failure of standard wound care must be documented. This coverage determination, periodically reviewed, reflects the Centers for Medicare & Medicaid Services’ assessment that sufficient evidence supports HBOT’s value in this population.
Private insurers vary in their coverage policies, with some requiring prior authorization or documented failure of alternative therapies. The 2026 GRADE assessment of moderate-certainty evidence may influence future coverage determinations, potentially expanding access for appropriately selected patients.
The Safety Profile: Generally Favorable but Not Negligible
HBOT’s safety record in diabetic foot ulcer populations is generally favorable, though not without considerations. Barotrauma affecting the middle ear or sinuses represents the most common adverse effect, occurring in a minority of patients and typically manageable with pressure-equalization techniques or temporary treatment interruption.
Oxygen toxicity affecting the central nervous system or lungs is rare at the pressures and durations typically employed for wound healing. Hypoglycemia during treatment sessions requires particular attention in diabetic patients, necessitating glucose monitoring and appropriate management protocols.
The 2025 FDA safety communication regarding hyperbaric device fire risks and proper operational protocols applies to all HBOT applications, including diabetic foot ulcer treatment. This reminder underscores the importance of treatment in accredited facilities with appropriate safety systems and trained personnel.
Practical Implications for Clinical Decision-Making
For clinicians managing diabetic foot ulcers, the 2026 evidence syntheses offer several practical guideposts. HBOT should be considered for patients with Wagner Grade III or IV ulcers that have demonstrated inadequate response to four weeks or more of standard wound care, including offloading, debridement, and infection management. Ischemic wounds may derive particular benefit, though revascularization should be pursued when anatomically feasible.
Referral to an accredited hyperbaric facility allows comprehensive evaluation of candidacy, including vascular assessment, infection control status, and glycemic management. Treatment typically involves 30 to 40 sessions over six to eight weeks, requiring substantial patient commitment and logistical coordination.
Realistic counseling is essential. HBOT is an adjunctive therapy, not a standalone solution. Continued wound care, pressure offloading, and metabolic optimization remain foundational. Complete healing is not guaranteed, and the primary goal—limb preservation—must be weighed against treatment burden and cost.
Looking Forward: Research Priorities
The 2026 reviews identify several priorities for advancing the evidence base. Standardized outcome definitions would enable more meaningful comparison across trials. Investigation of predictive biomarkers or clinical characteristics could refine patient selection. Comparative effectiveness research pitting HBOT against emerging therapies—topical oxygen systems, placental-derived products, or advanced cellular therapies—would inform treatment sequencing decisions.
Longer-term follow-up in future trials would address the durability question that has persisted since the original Cochrane review. Health economic analyses incorporating the substantial costs of amputation and subsequent rehabilitation would clarify HBOT’s value proposition for healthcare systems and payers.
For now, hyperbaric oxygen therapy remains a reasonably supported option in the diabetic foot ulcer armamentarium—neither the panacea some enthusiasts suggest nor the expensive placebo skeptics dismiss. The moderate-certainty evidence identified in 2026 provides sufficient foundation for clinical use in appropriately selected patients, while the identified gaps in knowledge should guide both clinical humility and research investment.
Sources
- MDPI — Comparative Certainty of Evidence for Diabetic Foot Ulcer Therapies (2026)
- The Mayer Institute — HBOT for Diabetic Foot Ulcers: Mechanisms, Evidence, and Clinical Limits (2026)
- Cochrane Library — Hyperbaric oxygen therapy for chronic wounds (Kranke et al., 2015)
- CMS — National Coverage Determination 20.29: Hyperbaric Oxygen Therapy
- FDA — Hyperbaric Oxygen Therapy: Get the Facts